Articles tagged with Breast Cancer
Researchers at the University of Illinois found that benign and cancerous breast calcifications have unique structures and formation processes. The study provides a new classification scheme and opens the possibility of treating benign calcifications using certain drugs.
A contemporary cohort study found a low risk of isolated locoregional recurrence (5.6%) at 10.1 years follow-up for young women diagnosed with breast cancer under 40. Surgical decision-making should not be influenced by concerns about long-term risk.
City of Hope research demonstrates a new drug combination that slows advanced prostate cancer growth without improving overall survival. A novel AI conversation tool helps scientists uncover gene-disease connections without programming expertise.
A study documents elite-level strength training during active breast cancer treatment, showing rare retention of squat strength despite chemotherapy. LaShae Rolle, a competitive powerlifter and breast cancer survivor, completed the first-of-its-kind study, demonstrating the feasibility of high-intensity training when carefully managed.
A combination of two approved cancer medications may slow or reverse Alzheimer's symptoms by reversing gene expression changes in neurons and brain cells. Researchers analyzed public data from deceased donors and found a link between these drugs and reduced risk of developing the disease.
A new study published in JAMA Network Open found no statistical relationship between pathologic complete response (pCR) and overall survival in rectal cancer patients. This challenges the FDA's use of pCR as a surrogate endpoint for drug approval, which may lead to treatments being fast-tracked without evidence of improved long-term su...
Researchers found that tirzepatide reduced body weight and body fat by approximately 20% in mice, resulting in a significant reduction of tumor volume. The study suggests that this new anti-obesity drug may have a beneficial impact on breast cancer outcomes.
Researchers identified RTK dependent and independent mechanisms of resistance to EGFR targeted therapies in breast and head and neck cancers, highlighting opportunities for combination therapies and biomarker identification.
A recent analysis of 16 years of data on Japanese adults reveals a strong association between socioeconomic status and the incidence of five common cancers. Communities with low employment rates or low incomes show higher cancer rates compared to those with higher socioeconomic status.
Researchers at Boston University have found that exosomes released by obese tissues can turn slow-moving TNBC cells into highly mobile and invasive ones. This discovery could lead to the development of non-invasive biomarkers for metastatic risk and new drug targets like Rho-protein inhibitors.
The interplay between exosomes and metabolic reprogramming shapes breast cancer progression and resistance. Targeting this axis offers novel diagnostic and therapeutic strategies, including exosome-based liquid biopsy techniques and combination therapies.
A study published in Radiology found that AI decision support systems improve breast cancer detection accuracy and visual search patterns among radiologists. With AI assistance, radiologists spend more time examining regions with actual lesions, leading to better performance and efficiency.
A study of 168,547 postmenopausal women found that excess weight is associated with a 31% higher risk of breast cancer in those with cardiovascular disease. Higher BMI also increases the risk in women without cardiovascular disease, although to a lesser extent.
Researchers discovered that breast cancer responds to CDK4/6 inhibitors by forming an immunosuppressive microenvironment, which can be mitigated with radiation therapy or immune-modulating drugs. The study also found a potential biomarker to predict treatment response in patients.
Researchers have discovered a hidden switch in breast cancer that uncovers PHGDH's role as both a metabolic and transcriptional regulator. PHGDH suppresses genes vital for immune cell function, steering macrophages toward tumor-fighting behavior. The study offers promising new strategies for reprogramming the tumor microenvironment.
A novel nanocarrier system utilizing metal-polyphenols enables precise intracellular delivery of therapeutic antibodies into cancer cells. This technology overcomes endosomal entrapment, resulting in suppressed tumor growth and enhanced anti-cancer activity.
A recent survey by the Annenberg Public Policy Center found that nearly half of Americans believe women should begin regular mammograms at age 40, while younger women are less certain. Women aged 18-29 were most likely to choose an incorrect age, with 27% selecting 30 years old as the start age.
A computational study found amygdalin to be a promising therapeutic agent for HER2-positive breast cancer. The compound shows favorable binding energies and induces structural changes in the HER2 protein, suggesting its potential to suppress cancer-promoting activity.
A new study by the NIH found that hormone therapy may alter breast cancer risk in women under 55. Women treated with unopposed estrogen hormone therapy were less likely to develop breast cancer, while those using estrogen plus progestin hormone therapy were more likely to develop the disease.
A new AI-assisted technique called PACT has been developed to help differentiate between suspicious and healthy tissue in breast imaging. The method, which combines light and sound into a single modality, performs as well as or better than conventional techniques like mammography and MRI.
Researchers have identified LINC01235 as a crucial regulator of NFIB expression and NOTCH pathway in TNBC, suggesting potential therapeutic targets for this aggressive form of breast cancer. The study provides new insights into the role of non-coding RNAs in cancer progression.
Breast cancer metastasis relies heavily on mitochondrial oxidative metabolism, with adaptations including lipid metabolism and oxidative phosphorylation. Targeting mitochondrial fission, fusion, and mitophagy shows promise in preclinical models, while challenges remain due to heterogeneity and drug resistance.
This study examines breast cancer incidence trends in older US women by racial and ethnic groups, geographic location, and cancer stage. The analysis reveals differing patterns across age groups, highlighting the importance of considering screening guidelines when analyzing breast cancer incidence rates.
The Association for Molecular Pathology publishes guidelines for detecting homologous recombination deficiency (HRD) in cancer. The report includes recommendations for clinical laboratories, addressing technical aspects of genomic instability and HRD analysis.
Researchers developed an AI tool called AAnet to characterize cancer cell diversity, identifying five distinct cell groups with different gene expression profiles. This could lead to more targeted therapies and improved patient outcomes.
The BRACELET-1 trial demonstrated a 20% objective response rate and 12.1-month progression-free survival for patients with unresectable HR+ HER2- tumors, suggesting that adding pelareorep to paclitaxel chemotherapy warrants further investigation in metastatic breast cancer.
Researchers developed nanomachines that can efficiently deliver antisense oligonucleotides to sentinel lymph nodes, reducing TGF-β1 levels and reactivating depleted CD8-positive T cells. This enhances cancer treatment outcomes for advanced breast cancers with no effective treatments.
A cohort study found breast cancer survivors have a lower risk of Alzheimer's dementia compared to cancer-free controls. Certain cancer treatments may confer benefits for reducing AD risk in this population.
A comprehensive review highlights the impact of anti-cancer treatments on bone health, increasing the risk of fractures and bone fragility. The International Osteoporosis Foundation advocates for a multidisciplinary approach to early screening and proactive bone-protective strategies.
Researchers developed a tool to monitor treatment response in patients with solid tumours using circulating tumour DNA analysis, anticipating clinical relapses up to 68 months before symptoms become apparent. The technology is minimally invasive and can be tailored to each tumour type, reducing unnecessary treatments and costs.
Scientists at MSK found that certain metabolites play a key role in driving differentiation in stem cells, potentially leading to improved tissue regeneration and healing for conditions involving chronic inflammation. APOBEC3 enzymes were linked to breast cancer resistance and growth, with implications for treatment.
The UNC Lineberger Comprehensive Cancer Center has developed an adaptive clinical trial for metastatic breast cancer, leveraging $28 million in funding from the Advanced Research Projects Agency for Health (ARPA-H). The study aims to adapt treatment plans in near real-time using tumor biopsies, blood samples, and biomarkers.
A new dual-laser strategy revolutionizes breast cancer photothermal therapy by minimizing damage to surrounding tissues while effectively ablating tumors. The approach uses near-infrared photothermal agents with aggregation-induced emission properties and achieves precise targeting through second NIR-II fluorescence imaging technology.
A new study of 591 women with early-stage breast cancer found that nearly two-thirds opted for continued endocrine therapy beyond the initial five years. Patients with higher-risk stage 2 disease were more likely to continue treatment, highlighting potential benefits in extending hormone-based therapy for these patients.
A newly developed molecular imaging technique can identify multiple subtypes of triple-negative breast cancer, improving diagnostic capacity. The approach targets extra domain A of fibronectin, a stable protein in the tumor stromal environment abundantly expressed in breast cancer.
MOME achieves expert-level accuracy in classifying tumor malignancy and reduces unnecessary biopsies by identifying benign cases. The AI model also predicts treatment responses and subtypes triple-negative breast cancer.
Dr. Nikolaos Koundouros has been awarded the 2025 Tri-Institutional Breakout Award for his research on how cells detect and respond to dietary nutrients, specifically omega-6 and omega-3 fatty acids, in relation to breast cancer development.
Researchers have found that soft tumour tissue enables cancer cells to hide from the immune system, potentially speeding up disease progression. This discovery may help doctors identify patients unlikely to benefit from immunotherapy, guiding them towards alternative treatments.
Researchers at the University of Turku have developed a new fluorescent probe, Illusia, to visualize signaling dynamics in moving cancer cells. This tool has led to a new therapeutic possibility for limiting breast cancer spread, with potential implications beyond breast cancer.
A recent randomized controlled trial found that a group-based intervention fostering communication and coping skills in a culturally tailored way improved outcomes for Latina breast cancer survivors and their caregivers. The study, published in CANCER journal, demonstrated high engagement among participants and clinically significant i...
A new drug combination has shown significant improvements in overall survival for patients with advanced breast cancer who have the PIK3CA gene mutation. The treatment, which includes inavolisib, palbociclib, and fulvestrant, was found to extend median overall survival by 7 months compared to the placebo group.
The CompassHER2 trial found that neoadjuvant THP led to a pathologic complete response (pCR) rate of 64% in patients with early-stage HER2-positive, ER-negative breast cancer. Lower ER expression levels resulted in higher pCR rates among ER-positive tumors.
Researchers at Ohio State University have developed blood tests to diagnose pancreatic cancer and predict treatment outcomes. Genetic information can also help predict breast cancer survival rates, while a new blood test may improve treatment response for patients with advanced sarcoma. These findings offer promising tools for early de...
A multi-center clinical trial found that Duavee, a menopause drug, significantly reduced cell growth in breast tissue and was well-tolerated by participants. The study suggests that Duavee may offer a promising alternative for women at elevated risk of invasive breast cancer due to personal or family history.
A new study analyzed trends over time in alcohol-linked cancer mortality across the US, finding nearly double the number of alcohol-related cancer deaths between 1990 and 2021. The burden is highest among men over 55, with liver, colorectal, and esophageal cancers seeing significant increases.
The foundation recognizes five early-career scientists who apply computational methods to cancer research, with a focus on developing new protein designs and understanding chromatin modifications. Their work aims to improve treatment strategies and precision oncology for various cancers.
Emerging imaging technologies like Tomosynthesis, Contrast-Enhanced Spectral Mammography, and Molecular Breast Imaging improve detection of high-risk populations and dense breast tissue. AI Integration, Noninvasive Biomarkers, and Hybrid Techniques hold promise for reducing radiation risks and overdiagnosis.
Researchers from Mayo Clinic Comprehensive Cancer Center will present practice-changing studies on chemotherapy approaches, AI applications in oncology, and new therapies for breast and melanoma. The event will feature 59 abstracts highlighting advancements in cancer care.
A study by researchers at the University of São Paulo found that women with low muscle mass have a significantly lower survival rate than those with normal muscle mass. Muscle mass is crucial for patients undergoing cancer treatment, and low levels can predict adverse outcomes, including mortality.
Researchers from City of Hope will present novel cancer treatment approaches and combinations, including innovative combination therapies for breast, genitourinary, and gastrointestinal cancers. Additionally, they'll discuss the safety of readministering trastuzumab-deruxtecan to metastatic breast cancer patients with low-grade lung co...
A randomized controlled trial found that additional imaging techniques such as fast MRI and contrast mammography can detect early-stage cancers in women with dense breasts that were missed by mammograms. The study showed a cancer detection rate of 1.7% for fast MRI and 1.9% for contrast mammography, compared to 0.4% for ultrasound.
A new study by Queen Mary University of London found significant ethnic differences in breast cancer development and outcomes among women of African and South Asian genetic ancestry. Women from these backgrounds were diagnosed earlier and died younger than European-ancestry women, highlighting the need for tailored care approaches.
A new study published in Radiology found that abbreviated breast MRI is an effective screening method for women with extremely dense breasts, detecting cancer while reducing scan times by up to 80%. The abbreviated protocol retains a high level of diagnostic accuracy comparable to the full protocol MRI.
Dr. Alana Welm has been appointed as the Chair of Oncological Sciences, leading efforts to advance research, education, and clinical impact. With a focus on innovation and collaboration, she aims to foster a culture of excellence and position the department for national distinction.
Researchers found that denosumab increases tumour-infiltrating immune cells in early-stage breast cancer patients, particularly in type B luminal tumours. This increase is associated with a potential boost to the anti-tumor immune response and offers a valuable avenue for clinical interest.
A recent study identifies LPCAT1 as a critical culprit in TNBC's aggressive behavior, which can be silenced with siRNA-delivering nanoparticles. This approach starves tumors of their energy supply, dramatically reducing tumor growth and lung metastasis.
A systematic review and meta-analysis found that individuals with blood type A have a significantly higher risk of developing breast cancer compared to those with blood type O. The research, which pooled data from over 13,000 breast cancer patients and 717,000 controls, suggests an 18% increased risk associated with blood type A.
A new treatment approach significantly improves survival rates for patients with aggressive, inherited breast cancers. In a trial where cancers were treated with chemotherapy followed by a targeted cancer drug before surgery, 100% of patients survived the critical three-year period post-surgery.
A University at Buffalo study found that historically redlined neighborhoods have a disproportionate impact on breast cancer factors and survival, with lower socioeconomic status and exposure to pollution contributing to the increased risk. The research suggests that addressing environmental disparities in these communities is crucial ...
A new study suggests that multi-strain probiotics can alleviate chemotherapy-related side effects such as fatigue, nausea, and weakness. Probiotics have been shown to improve blood urea nitrogen levels and enable patients to perform daily activities more independently.